Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis

European Journal of Surgical Oncology

Volumn 41, Issue 1, 2015, Pages 120-127

  Al Adra, D P ^a   Gill, R S ^a   Axford, S J ^b   Shi, X ^c   Kneteman, N ^a   Liau, S S ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ST GEORGE S UNIVERSITY   (Grenada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cholangiocarcinoma; Radioembolization; Yttrium 90 microsphere

Indexed keywords

MICROSPHERE YTTRIUM 90; UNCLASSIFIED DRUG; YTTRIUM 90; MICROSPHERE; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; HUMAN; INOPERABLE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOEMBOLIZATION; SURVIVAL RATE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTIFICIAL EMBOLIZATION; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DISEASE FREE SURVIVAL; INTRAHEPATIC BILE DUCT; META ANALYSIS; PROCEDURES;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; HUMANS; MICROSPHERES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84922526721     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.09.007     Document Type: Article

References (33)

1. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol 2004 Mar;40(3):472-7.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001 Jun; 33(6):1353-7.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 Jane Feb;55(1):10-30.
4. Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010 Aug;90(4):817-37.
5. Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinomaea population-based study. Ann Surg Oncol 2008 Feb;15(2):600-8.
6. Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 1998 Oct;187(4):365-72.
7. Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen CL. Surgical treatment of cholangiocarcinoma. Hepatogastroenterology 1997 MayeJun;44(15):760-5.
8. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 Apr 8; 362(14):1273-81.
9. Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: A 2-center study. Cancer 2011 Apr 1;117(7):1498-505.
10. Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008 Oct 1;113(7):1614-22.
11. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of highdose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005 Dec 1;23(34):8739-47.
12. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006 Oct;17(10):1571-93.
13. Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R. Yttrium- 90 radioembolization in the management of liver malignancies. Semin Oncol 2010 Apr;37(2):94-101.
14. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011 Feb;140(2):497-507.e2.
15. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 2010 Jan; 138(1):52-64.
16. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 2012 Aug;35(4):393-8.
17. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008 Jun; 31(3):271-9.
18. Bower G, Little A. Experience with selective internal radiotherapy for patients with intrahepatic cholangiocarcinoma. Intern Med J April 2013;43:5.
19. Camacho JC, Kokabi N, Schuster DM, Kim HS. PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study. J Clin Oncol 20 May 2013;31(15 Suppl. 1).
20. Camacho JC, Kokabi N, Prajapati HJ, El-Rayes B, Kim HS. Modified mrecist criteria responses at an early time point by contrast enhanced imaging predicts survival in patients with unresectable intrahepatic cholangiocarcinoma (ICC) refractory to standard chemotherapy following intra-arterial yttrium-90 (Y-90) resinbased radioembolization. J Vasc Interv Radiol May 2013;24(5):759.e14-5.
21. Chaiteerakij R, Schmit GD, Mettler TA, et al. Comparison of transarterial radioembolization (Tare) and transarterial chemoembolization (TACE) for the treatment of unresectable intrahepatic cholangiocarcinoma. Gastroenterology 2011 May;140(5):S920-1.
22. Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012 Feb;35(1):105-16.
23. Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis. Ann Surg Oncol 2013 Nov;20(12):3779-86.
24. Martinez BK, Flanders V, Gupta NK, Natarajan K, Underhill MP, Cooke J. Development of a Y90 radioembolization program in a community hospital setting for treatment of metastatic and primary liver tumors. J Vasc Interv Radiol May 2013;24(5):759.e32-3.
25. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013 Aug;24(8):1227-34.
26. Prajapati HJ, Lawal TO, McIntosh EB, El-Rayes BF, Kauh JS, Kim HS. Yttrium-90 radioembolization for chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC): survivals and prognostic factors. J Vasc Interv Radiol June 2012;23(6):853.e17-8.
27. Turkmen C, Ucar A, Poyanli A, et al. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm 2013 Sep;28(7):534-40.
28. Saxena A, Bester L, Chua TC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. Ann Surg Oncol 2010 Feb; 17(2):484-91.
29. Shridhar R, Sweeney J, Biebel B, Hoffe SE, Choi J, Arslan B. Shortterm outcomes of intrahepatic cholangiocarcinoma treated with glass based yttrium 90 microspheres. J Vasc Interv Radiol March 2012; 23(3 Suppl. 1):S84-5. Conference: 37th Annual Scientific Meeting of the Society of Interventional Radiology 2012 San Francisco, CA United States.
30. Ray CE, Edwards A, Smith MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapybased transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol August 2013; 24(8):1218-26.
31. Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases e a systematic review. Surg Oncol 2012 Dec;21(4):299-308.
32. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013 Mar;57(3):1078-87.
33. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007 May 1;68(1):13-23.